Dr. Sanjay Gupta

When I interviewed some of the scientists at Novo Nordisk in Denmark, one of the things they said to me, interestingly, was that they sort of slow rolled the idea of using these medications for weight loss initially.

And they were very specific about it.

They just didn't think people would inject themselves for weight loss.

Diabetics do for insulin, but the idea that it would become as widespread as it has, that surprised them when I was interviewing them in retrospect.

But even at that time, there was a desire to say, hey, look, could we potentially turn this into a pill?

And they've done that now, and this is something you've been reporting on a lot.

First of all, why was that so challenging?

So it gets churned up by your gastric acids and everything in your stomach.

Oh, I didn't know that.

Thankfully, it's been approved.

Calling it the Wegovy pill for a second, how does it compare to the injection in terms of how well it works and side effects?

And we'll have much more on the evolving landscape of GLPs with my colleague Meg Terrell right after this short break.

Let's talk about cost.

And even before comparing the pill to the injection, we heard about the President Trump plan to reduce costs.

How has that sort of played out for the average consumer?

And what was it before that?

What was the average price?

So significant drop.

Less than what it was.

So were Eli Lilly and Novo Nordisk, were they good with this plan?